PF-4708671

Name: PF-4708671
Brand: Selleck Chemicals
SKU: S2163
Rating: 5 (16 reviews)

For research use only.

Licensed and Manufactured by Pfizer Catalog No.S2163

16 publications

Molecular Weight(MW): 390.41

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with K_i/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. PF-4708671 induces autophagy. First S6K1-specific inhibitor to be reported.

Selleck's PF-4708671 has been cited by 16 publications

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Theranostics, 2019, 9(19):5464-5477

PubMed: 31534497 ( click the link to review the publication )

Oncogene, 2019, 38(35):6270-6282

PubMed: 31316145 ( click the link to review the publication )

Platelets, 2019, 30(2):241-250

PubMed: 29257917 ( click the link to review the publication )

Nutr Metab (Lond), 2018, 10.1186/s12986-018-0268-9

PubMed: 29743930 ( click the link to review the publication )

Cell Death Dis, 2017, 8(1):e2553

PubMed: 28079897 ( click the link to review the publication )

Front Immunol, 2017, 7:685

PubMed: 28138329 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9163-74

PubMed: 26824321 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(3):799-809

PubMed: 25573956 ( click the link to review the publication )

J Immunol, 2015, 195(6):2529-39

PubMed: 26276876 ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: ( click the link to review the publication )

Toxicol Lett, 2015, 233(2):102-113

PubMed: 25597859 ( click the link to review the publication )

Cell Immunol, 2015, 298(1-2):9-17

PubMed: 26302934 ( click the link to review the publication )

Cell Signal, 2015, 27(11):2191-200

PubMed: 26210887 ( click the link to review the publication )

PLoS One, 2014, 9(2):e90388

PubMed: 24587347 ( click the link to review the publication )

Oncotarget, 2014, 5(10):3145-58

PubMed: 24762669 ( click the link to review the publication )

5 Customer Reviews

After treated with PF-4708671 (PF, 10 uM) and 4EGI-1 (50 uM) for 48 h, GRP78 and ATF4 in QBC939, RBE and HCCC-9810 cells were analyzed using western blot.

PLoS One 2014 9(2), e90388. PF-4708671 purchased from Selleck.
(F) EGR-2 and GFI-1 abundance (n = 5).

Front Immunol, 2017, 7:685. PF-4708671 purchased from Selleck.
Tumor sections were examined for DNA fragmentation (TUNEL) or stained with Ki-76 antibody. The representative images are shown. The brown color indicates the positively stained cells; scale bar, 50 mm.

Mol Cancer Ther, 2015, 14(3): 799-809. PF-4708671 purchased from Selleck.
C. Cell lines were treated with the indicated compounds for 24h. ABC cells are colored in red. GCB are colored in blue. Intermediate cells are colored in gray.

Oncotarget, 2016, 7(8):9163-74. PF-4708671 purchased from Selleck.
Effect of PF-4708671 on lipid accumulation and expression of lipogenic genes in HepG2 cells. Cells were exposed to 6 μM PF-4708671, 144 μM PA (sodium palmitate), or 14 nM RAPA (Rapamycin) for different periods of time. (b) The intracellular lipid content in each group was quantified. (c) Detection of TG levels.

Nutr Metab (Lond), 2018, 15:31. PF-4708671 purchased from Selleck.

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Description

Targets

p70 S6K1 ^[1]
(Cell-free assay)

160 nM

In vitro

PF-4708671 is a piperazinyl-pyrimidine analogue and the first S6K1-specific inhibitor. PF-4708671 does not significantly inhibit the activity of the closely related S6K2 isoform or a number of other AGC kinases (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 or SGK1) . PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), while having no effect upon the PMA-induced phosphorylation of substrates of the highly related RSK (p90 ribosomal S6 kinase) and MSK (mitogen- and stress-activated kinase) kinases. PF-4708671 is also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1). PF-4708671 does not affect activity of mTORC1. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
BHT-101	NUHmSFZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;Wb2lEPTB;MD64NlAzPCEQvF2=	M{HuPXNCVkeHUh?=
UACC-893	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DUbWlEPTB;NT6xPVg5PiEQvF2=	M2XP[XNCVkeHUh?=
A427	Ml\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{mzVWlEPTB;NT63NlU3PyEQvF2=	M1L2bXNCVkeHUh?=
OCUB-M	M13Pemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jDcGlEPTB;Nj62OlExOiEQvF2=	M3Xrc3NCVkeHUh?=
SW684	M1Paemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPEXXc6UUN3ME23MlUzOjZ6IN88US=>	NYX3WG5PW0GQR1XS
SK-LMS-1	M3nRPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXtTWM2OD17LkCxN\|AzKM7:TR?=	Ml3xV2FPT0WU
CP50-MEL-B	MkWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH3hS3pKSzVyPUmuN\|A1OTlizszN	NV\TO\|VnW0GQR1XS
NCI-H1651	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDSXnFlUUN3ME2xNE4xOjd4IN88US=>	NYrhXFFQW0GQR1XS
ABC-1	NWjT[ZNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LJU2lEPTB;MUCuNVA{PyEQvF2=	NHnFNWNUSU6JRWK=
OE19	NHLLR2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTFyLkG3N\|Mh\|ryP	NGTlVGhUSU6JRWK=
DSH1	MlfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3aO\|dPUUN3ME2xNE45QDd7IN88US=>	MVPTRW5ITVJ?
SW13	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPJTWM2OD1zMT65N\|E6KM7:TR?=	NYXBTmE4W0GQR1XS
MDA-MB-453	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTF{LkG2NFMh\|ryP	NFjPSHBUSU6JRWK=
647-V	NVHIXGRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIqzR2xKSzVyPUGyMlM2QDJizszN	M{S1VnNCVkeHUh?=
NCI-H2342	NH7meVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFS4OIFKSzVyPUGyMlM6QTVizszN	NETiZXdUSU6JRWK=
LB2241-RCC	NWO4Nm45T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfrVWtKSzVyPUGyMlU4PzlizszN	M1XFZnNCVkeHUh?=
UACC-257	NUL3eFVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHniUo1KSzVyPUGzMlQ1PTNizszN	MXXTRW5ITVJ?
NCI-H661	Mn;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUGyToxoUUN3ME2xN{43PDR7IN88US=>	MkfKV2FPT0WU
FADU	Mn;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk[yTWM2OD1zMz62PVkzKM7:TR?=	NIDHTYxUSU6JRWK=
A2780	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2q5UmlEPTB;MUOuPFA1OSEQvF2=	MUHTRW5ITVJ?
NCI-H1793	NG[2UYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIX3VJVKSzVyPUG0MlQxQDVizszN	NEnld2VUSU6JRWK=
TE-8	M1\sbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPlTWM2OD1zNT6zOFY2KM7:TR?=	M3nMRXNCVkeHUh?=
HGC-27	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfwb4M6UUN3ME2xOk4yPjR2IN88US=>	NWrIVWZJW0GQR1XS
MMAC-SF	MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjtTWM2OD1zNz6zO\|I4KM7:TR?=	M37kfnNCVkeHUh?=
Calu-6	MmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTF6LkG1NVMh\|ryP	NWfLb3dnW0GQR1XS
HUTU-80	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTF6LkO5OVkh\|ryP	MUPTRW5ITVJ?
SAS	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoH1TWM2OD1zOD62OFU2KM7:TR?=	M{T2VXNCVkeHUh?=
IST-MES1	MljrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\ve2lEPTB;MUiuOlUxQCEQvF2=	Mo\XV2FPT0WU
C3A	NFG0SmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mni3TWM2OD1zOD63PVE6KM7:TR?=	NFvIWGtUSU6JRWK=
ES3	NY\sdWpmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTF6LkizOlQh\|ryP	NUTG[ocxW0GQR1XS
HSC-2	MnXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vod2lEPTB;MUmuOlU1OSEQvF2=	M{jyS3NCVkeHUh?=
T47D	NX2xUohWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvBSHc{UUN3ME2yNE4yPDh3IN88US=>	Mon4V2FPT0WU
EW-7	M1TVVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1jsUmlEPTB;MkCuPFU5QCEQvF2=	MUDTRW5ITVJ?
LN-405	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTJyLki5OlUh\|ryP	NF3PWGJUSU6JRWK=
U031	NXPkVYFJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTJzLkS4NFIh\|ryP	Mlj6V2FPT0WU
A549	M1ricmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1S3NGlEPTB;MkGuPFQ6OSEQvF2=	MX;TRW5ITVJ?
RMG-I	MoDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3L5[WlEPTB;MkKuNlY3QCEQvF2=	MmnKV2FPT0WU
BT-474	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3jTWM2OD1{Mj62OVUyKM7:TR?=	NWm4fYk{W0GQR1XS
NB69	NGfldpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHVTWM2OD1{Mz6xOVIh\|ryP	NUG2[WZiW0GQR1XS
NB7	MlnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HYVGlEPTB;MkSuNVg5KM7:TR?=	M4TyXHNCVkeHUh?=
HCC1569	Mn74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;rTWM2OD1{ND62NVI2KM7:TR?=	MV3TRW5ITVJ?
MEL-JUSO	M3rudmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfqW\|NKSzVyPUK0MlY6ODhizszN	NHPZS5NUSU6JRWK=
MDA-MB-175-VII	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonITWM2OD1{NT6yOVE4KM7:TR?=	MkTjV2FPT0WU
HCC1419	NX7nbpJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rGRmlEPTB;MkWuOlAxOyEQvF2=	MX3TRW5ITVJ?
Ca9-22	MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPEWWhzUUN3ME2yOU43PDN{IN88US=>	MojnV2FPT0WU
KGN	NHXpOoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XoZmlEPTB;MkWuO\|U1PyEQvF2=	M3GwN3NCVkeHUh?=
LB373-MEL-D	NY\uTGZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFW1T4NKSzVyPUK2MlE6OzhizszN	MkXnV2FPT0WU
NCI-H1755	MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LiS2lEPTB;Mk[uPFg1OSEQvF2=	M1qxR3NCVkeHUh?=
D-423MG	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTJ5LkC3NVUh\|ryP	MnL5V2FPT0WU
DK-MG	NEXSPJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PlTGlEPTB;MkiuO\|g1PiEQvF2=	NE\3UVRUSU6JRWK=
NCI-H1623	NWfPXHBQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnYcFZZUUN3ME2yPE45OzR{IN88US=>	MlLJV2FPT0WU
KU-19-19	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELTcZJKSzVyPUK4Mlk6PSEQvF2=	MnzNV2FPT0WU
C-33-A	M2Dsbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXWzeI05UUN3ME2yPU4zOTl6IN88US=>	NUfSfG9uW0GQR1XS
SCC-4	MofpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTNyLkOzOVQh\|ryP	MmPWV2FPT0WU
MG-63	MkTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTNyLkW5PVQh\|ryP	NV3FfJk6W0GQR1XS
LNCaP-Clone-FGC	NHTtcFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTNzLkS5NlEh\|ryP	NIXEbGhUSU6JRWK=
CAPAN-1	Mk\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnyV5J3UUN3ME2zNU42Ojh4IN88US=>	MVnTRW5ITVJ?
GI-ME-N	NWO0PVAzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvDZpJKSzVyPUOxMlU{PTNizszN	NYfGU4JkW0GQR1XS
RERF-LC-MS	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TJXWlEPTB;M{KuOlc1PyEQvF2=	NHzIWYdUSU6JRWK=
KLE	Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\2dGlEPTB;M{OuOFM{PCEQvF2=	NUjkeHVsW0GQR1XS
KNS-81-FD	M3XTeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGK4d49KSzVyPUOzMlUxODhizszN	MkfHV2FPT0WU
DOK	NV[zd4duT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkT5TWM2OD1\|ND62OlEzKM7:TR?=	NGTiVXdUSU6JRWK=
ACHN	MnzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;NSGlEPTB;M{WuNVU5QCEQvF2=	M1S3WnNCVkeHUh?=
KYSE-520	M1jKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTN3LkKzOlEh\|ryP	NIPpR5JUSU6JRWK=
SBC-5	M1vlTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTN3LkWxNVYh\|ryP	NILyc2ZUSU6JRWK=
NCI-H28	NHnCWXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfSXWhKSzVyPUO1MlY3QTVizszN	MljQV2FPT0WU
ES7	NX2yVGNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\4W2lEPTB;M{[uNlI1QSEQvF2=	NI\3[oJUSU6JRWK=
A172	NXvt[nhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\TfodKSzVyPUO2MlQyQDdizszN	NEjiN21USU6JRWK=
UM-UC-3	M{XG[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnBTWM2OD1\|Nz64O\|Q3KM7:TR?=	MofDV2FPT0WU
LXF-289	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPPdZZKSzVyPUO4MlAxPDdizszN	MmT1V2FPT0WU
KP-4	NInQNIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTN6LkS3N\|kh\|ryP	MX;TRW5ITVJ?
TE-1	MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;0TWM2OD1\|OT62OVg6KM7:TR?=	M1HRN3NCVkeHUh?=
G-402	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTRyLkC2NUDPxE1?	M{PCc3NCVkeHUh?=
786-0	M3nzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2[2OGlEPTB;NECuPVA6PiEQvF2=	MkHyV2FPT0WU
K5	M{G3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTRzLkO2PFYh\|ryP	M1[3V3NCVkeHUh?=
SK-N-DZ	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTRzLkO4NlMh\|ryP	MVPTRW5ITVJ?
OVCAR-4	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4n4PGlEPTB;NEGuO\|U3QCEQvF2=	NFzENlBUSU6JRWK=
T84	M4LYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4f6PWlEPTB;NEKuNVI3OyEQvF2=	Mn3vV2FPT0WU
GCIY	MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzxPIpLUUN3ME20N{4xQDB\|IN88US=>	NUPseVNrW0GQR1XS
BB49-HNC	NHW5bItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTR\|LkOzOFgh\|ryP	MnniV2FPT0WU
SNU-C2B	NYXmNIhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkGwTWM2OD12Mz62OFM3KM7:TR?=	NFTVVWtUSU6JRWK=
TE-6	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3mxPWlEPTB;NEOuPFg6PCEQvF2=	M1jkN3NCVkeHUh?=
23132-87	Ml;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTR2LkK5O\|gh\|ryP	MXzTRW5ITVJ?
DMS-53	M3fsfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTR2LkOzPFQh\|ryP	M17teXNCVkeHUh?=
ONS-76	NX:4b\|lqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWr1cJQ{UUN3ME20OE44PjZzIN88US=>	NHi1eFVUSU6JRWK=
DMS-273	M2\MeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHrTWM2OD12ND65OFMh\|ryP	M3vyO3NCVkeHUh?=
COLO-824	NXP2dIVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrRXpZKSzVyPUS1Mlg4PzVizszN	NXHRWFBYW0GQR1XS
DMS-114	NHiw[VRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nH[GlEPTB;NEWuPFkzPyEQvF2=	NIWy[\|BUSU6JRWK=
YKG-1	NUHIPFE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\MVXVtUUN3ME20Ok4xOzV3IN88US=>	MmHHV2FPT0WU
RH-18	M4DKWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTR4LkO3N\|Mh\|ryP	M2DR[3NCVkeHUh?=
NCI-H1355	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTR4Lk[xPEDPxE1?	NV22ZYFJW0GQR1XS
NCI-H2170	NEjIemhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTR5Lke1PFQh\|ryP	M1fSWXNCVkeHUh?=
OC-314	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HUTmlEPTB;NEeuPFQ4QCEQvF2=	NXS4[FhnW0GQR1XS
NCI-H2030	NU\tbpFQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorOTWM2OD12Nz64PVA3KM7:TR?=	MkftV2FPT0WU
22RV1	NIqybIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{H6OmlEPTB;NEeuPVAyPSEQvF2=	NFHzOY5USU6JRWK=
G-401	Mm[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTITWM2OD12OD60OFE2KM7:TR?=	MVzTRW5ITVJ?
YAPC	Ml\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrn[G5KSzVyPUS5MlgxPzNizszN	NGjUc\|RUSU6JRWK=
SW1573	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1fZ[mlEPTB;NUCuNlQ{PSEQvF2=	NX;Bb3RFW0GQR1XS
COLO-792	M2DzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXrnNY1vUUN3ME21NE43OjN5IN88US=>	M2nJfXNCVkeHUh?=
KNS-62	NFvOdFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rLTWlEPTB;NUCuO\|UxQCEQvF2=	MlHUV2FPT0WU
NB5	M3vIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrMfmlPUUN3ME21NU41PTB7IN88US=>	NF\HUXVUSU6JRWK=
CP66-MEL	Mle2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTVzLk[0NFgh\|ryP	MYDTRW5ITVJ?
CaR-1	Ml3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnQUpNKSzVyPUWyMlA3ODZizszN	M363fHNCVkeHUh?=
CAL-54	NGntSmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfBTWM2OD13Mj6xNVAzKM7:TR?=	MoHlV2FPT0WU
8305C	MoftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWr0UphZUUN3ME21Nk4{OTVizszN	MoT4V2FPT0WU
Calu-3	NV34e2w{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXZXXJxUUN3ME21Nk4{PzN\|IN88US=>	MWTTRW5ITVJ?
AU565	Mn71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTV{LkW1NFkh\|ryP	MUXTRW5ITVJ?
CW-2	NYnFNpJUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XJZ2lEPTB;NUKuPFY2PCEQvF2=	NF:wbWRUSU6JRWK=
BEN	NUDnSIZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\aUYM{UUN3ME21N{44QDZ{IN88US=>	MXTTRW5ITVJ?
NCI-H1975	NI[yVXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\Nd3VNUUN3ME21N{45QTZ4IN88US=>	NXLHe45nW0GQR1XS
HCT-116	NV3TOYZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7OWmNWUUN3ME21OE4xOzJ5IN88US=>	MX7TRW5ITVJ?
SH-4	M2jEWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4DTZWlEPTB;NUSuNVM5KM7:TR?=	NYjQNpp{W0GQR1XS
NCI-H1693	NHjaXYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTV2LkKxNFMh\|ryP	MV7TRW5ITVJ?
BPH-1	NWnTSWtXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXkWlhKSzVyPUW1MlI5QTJizszN	NVq4UJZGW0GQR1XS
CAMA-1	NVfqWoM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXaSldiUUN3ME21OU45OTF4IN88US=>	Ml3wV2FPT0WU
A388	NVHnSI1{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTV4LkC5PFUh\|ryP	M4HtfHNCVkeHUh?=
C2BBe1	M4PsNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTV4LkK2N\|Qh\|ryP	NFmxZWpUSU6JRWK=
GAMG	NX[1VWpwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInJd2NKSzVyPUW2MlU6PTVizszN	MlHXV2FPT0WU
MKN28	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTV4LkiwNVMh\|ryP	NYn1RmxQW0GQR1XS
VA-ES-BJ	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnf0TWM2OD13Nj64O\|Q2KM7:TR?=	MY\TRW5ITVJ?
HuCCT1	MkLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPFXIFKSzVyPUW3MlA1QTJizszN	MWrTRW5ITVJ?
BFTC-905	NV;VWHBmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLlTWM2OD13Nz6yPFk5KM7:TR?=	MnPRV2FPT0WU
LS-123	M4\WZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmTLTWM2OD13Nz61OlY5KM7:TR?=	MVPTRW5ITVJ?
LB996-RCC	NIf4TYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnrR\|loUUN3ME21PE4xOjh5IN88US=>	NWrmfWZyW0GQR1XS
NCI-H1048	MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PvOGlEPTB;NUiuNlE5QCEQvF2=	M3raVXNCVkeHUh?=
COR-L105	NX;JVldGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTV6LkezN\|ch\|ryP	M4DkcXNCVkeHUh?=
OVCAR-8	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjhTnZQUUN3ME21PU4yPzF4IN88US=>	M{e5[XNCVkeHUh?=
SK-N-FI	M{foWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTV7LkOyNFch\|ryP	NYXISnRjW0GQR1XS
MES-SA	M{Lqfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUexWWY{UUN3ME21PU41PTB7IN88US=>	NIfBU3RUSU6JRWK=
SCC-9	Ml6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljWTWM2OD13OT60O\|U{KM7:TR?=	NUnMfop3W0GQR1XS
EFO-27	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX25OW9iUUN3ME21PU46PDNizszN	MU\TRW5ITVJ?
GT3TKB	NXu3TpdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjrR2lKSzVyPU[wMlYxPDhizszN	M2LZXXNCVkeHUh?=
HCC38	NHnjcWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG[3UHpKSzVyPU[xMlQ{PzlizszN	NIrKcJJUSU6JRWK=
MLMA	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHoTWM2OD14MT62NVY{KM7:TR?=	MYXTRW5ITVJ?
D-566MG	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jpVGlEPTB;NkOuOVIzPCEQvF2=	NG\tRlNUSU6JRWK=
SF295	MlvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXwTHI{UUN3ME22N{43PjV3IN88US=>	Mn\YV2FPT0WU
ES4	NVT0epJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrkeHVKSzVyPU[0MlQ4OTlizszN	NHOwVHlUSU6JRWK=
CAKI-1	NEfyO4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUT1[pk{UUN3ME22OE42PzJzIN88US=>	NUHVVGt1W0GQR1XS
OAW-28	M1\iVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TJdWlEPTB;NkSuPVY1PyEQvF2=	NWfkc3VoW0GQR1XS
NCI-H460	M3ziZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLsR4dKSzVyPU[1MlA5QTdizszN	MUHTRW5ITVJ?
JAR	M{\vd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzjTWM2OD14NT61OVE3KM7:TR?=	NGf5[WFUSU6JRWK=
SNU-449	MmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlewTWM2OD14NT63OlE3KM7:TR?=	MoHDV2FPT0WU
D-392MG	M4Xk[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTZ3Lkm0N\|Qh\|ryP	Mm\JV2FPT0WU
EW-22	NVzGW\|JmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIr2ZmJKSzVyPU[2MlM6PSEQvF2=	Mk\SV2FPT0WU
GCT	NG[3XnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jmbGlEPTB;NkeuNFQ1OyEQvF2=	M2TreXNCVkeHUh?=
NOS-1	NWfaOFdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWm2W\|dyUUN3ME22O{43QDZ5IN88US=>	MkPtV2FPT0WU
RH-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmm1TWM2OD14OD61OVU6KM7:TR?=	NFvlZ3JUSU6JRWK=
HuH-7	NH60S2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDWdG5mUUN3ME22PU4yODB{IN88US=>	MnPyV2FPT0WU
NUGC-3	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4W5cWlEPTB;N{CuPVY1PCEQvF2=	Ml;oV2FPT0WU
IST-SL1	M{LGb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTdzLkKzNlQh\|ryP	MULTRW5ITVJ?
SHP-77	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoD1TWM2OD15Mj6xNVkh\|ryP	M{\rR3NCVkeHUh?=
SW1116	M3WzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTd{LkG0NFch\|ryP	NGPURm9USU6JRWK=
LK-2	M1vK[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7XcYFlUUN3ME23Nk45PjF{IN88US=>	NFvyV2NUSU6JRWK=
U-2-OS	M2\tNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3KfVJKSzVyPUezMlE5OjhizszN	Mn\iV2FPT0WU
KYSE-150	Mom3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlS4TWM2OD15Mz62NVE5KM7:TR?=	NWTHSFFXW0GQR1XS
U251	NEjTS2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrvTWM2OD15Mz64NVY5KM7:TR?=	M3HoXXNCVkeHUh?=
HT-1080	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTd2LkK1O\|Qh\|ryP	NYL5ZVFQW0GQR1XS
NCI-H1437	NWroUlB2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTd2Lk[zNlYh\|ryP	M{X0SXNCVkeHUh?=
HPAF-II	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nmdGlEPTB;N{SuOlQyPSEQvF2=	NY\JcIw1W0GQR1XS
Becker	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTd3LkGxNFUh\|ryP	NEnRU4pUSU6JRWK=
PANC-10-05	M3Owbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUi3[mlsUUN3ME23OU4zQDZ3IN88US=>	MnqzV2FPT0WU
TYK-nu	NY[5VplYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzhTWM2OD15NT6zNVAzKM7:TR?=	NGDSOG1USU6JRWK=
SKG-IIIa	M3XRc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTd3LkOzOFEh\|ryP	Ml\QV2FPT0WU
NCI-H1993	NInZZnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTd3LkezPVch\|ryP	M1;vdnNCVkeHUh?=
S-117	NI[xT4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1:2eGlEPTB;N{WuO\|U2KM7:TR?=	M4LN[XNCVkeHUh?=
HuO9	NHHKcpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHFTWM2OD15Nj6wNFQ5KM7:TR?=	M4TifHNCVkeHUh?=
CAL-51	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrVU5lRUUN3ME23Ok4yODB4IN88US=>	MkKyV2FPT0WU
BT-20	MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPwOFlKSzVyPUe2MlIyPjhizszN	NV\NT4lKW0GQR1XS
LB831-BLC	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH:xeIRKSzVyPUe2MlMzOTdizszN	MWnTRW5ITVJ?
LB1047-RCC	NWewe5d5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnxTWM2OD15Nj63OlE6KM7:TR?=	MVjTRW5ITVJ?
ES8	MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M32yUWlEPTB;N{iuNFA4OyEQvF2=	M3;6OXNCVkeHUh?=
UMC-11	NXv0cmdZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml[2TWM2OD15OD6wPFg1KM7:TR?=	M2XwWXNCVkeHUh?=
NCI-H226	M4LMeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fne2lEPTB;N{iuNVMyPSEQvF2=	MWPTRW5ITVJ?
IGROV-1	NVXmUIV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTd6LkW1OUDPxE1?	MVnTRW5ITVJ?
BHY	NEPlV3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTd7LkW5OkDPxE1?	MY\TRW5ITVJ?
MKN45	NYDTVZBQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG[2W2FKSzVyPUiwMlMyPzRizszN	MWDTRW5ITVJ?
IA-LM	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTFTWM2OD16MD6zOVEyKM7:TR?=	NIPaXHBUSU6JRWK=
WM-115	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnme\|dKSzVyPUixMlQyOTRizszN	NWTVV\|N7W0GQR1XS
VMRC-RCZ	MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnuT3FKSzVyPUixMlQ1OjVizszN	M1P6dHNCVkeHUh?=
NCI-H2291	NWfzWGU5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVL4VJpDUUN3ME24NU43QDR{IN88US=>	NVXVNo4zW0GQR1XS
MCF7	Mn;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTh\|LkK4PVch\|ryP	NULPOHcyW0GQR1XS
639-V	M2P0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLzS5ZKSzVyPUi0MlYyOjlizszN	M4XWNnNCVkeHUh?=
RT4	NX7QU2ZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHjeVVKSzVyPUi1MlI1ODNizszN	NH[zbmNUSU6JRWK=
NCI-H2405	NVvwWG1nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTh3LkK5PVch\|ryP	M4TpfHNCVkeHUh?=
CAL-33	MkPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjrUlRKSzVyPUi1MlY{OTVizszN	NF3aT\|NUSU6JRWK=
BT-549	NUS3OY5qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfmTWM2OD16NT65N\|gzKM7:TR?=	MWLTRW5ITVJ?
HT-1197	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYL2VIExUUN3ME24PE4yODd5IN88US=>	M{PqRXNCVkeHUh?=
G-361	MnPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoH5TWM2OD16OD6xOFc1KM7:TR?=	NYPGcYozW0GQR1XS
LS-411N	M324eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTh7LkOzPFgh\|ryP	NITrT3hUSU6JRWK=
HT-144	NXK1dIlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17BNGlEPTB;OEmuOVk6OiEQvF2=	NVTHbmlkW0GQR1XS
DJM-1	M4PlOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zUNGlEPTB;OEmuPFg1PSEQvF2=	MWjTRW5ITVJ?
CAL-12T	M{LmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2jGWWlEPTB;OUCuO\|g6PSEQvF2=	M1\tPHNCVkeHUh?=
MKN7	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmP4TWM2OD17MT6zOVUyKM7:TR?=	MkDNV2FPT0WU
HuP-T3	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzaTWM2OD17Nj6xNFA1KM7:TR?=	M{X6SXNCVkeHUh?=
SK-MG-1	M3ToOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTJTWM2OD17Nj6xN\|Q5KM7:TR?=	MVvTRW5ITVJ?
NCI-H2347	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTl6LkGwOFIh\|ryP	MUHTRW5ITVJ?
SW872	M3y3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2L4bWlEPTB;MUCwMlQ2PiEQvF2=	M2TBVXNCVkeHUh?=
COLO-829	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTFyMD61OVMh\|ryP	M3zMXXNCVkeHUh?=
MC-IXC	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDrSmVWUUN3ME2xNFAvPjF3IN88US=>	MlO3V2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pS6 / S6 / pS6K / S6K1 / pAKT / AKT ; PubMed: 28626016 J Neurosci Western blot of cell lysates from neurons treated with PF-4708671, rapamycin, and Torin-2, individually or in combination for the indicated times. p-mTOR / mTOR / p-p70S6K / p70S6K ; PubMed: 30423811 Int J Mol Sci As determined using Western blotting, the phospho-p70S6K (p-p70S6K) inhibitor (PF-4708671) reduced the expression of phospho-mTOR (p-mTOR) and p-p70S6K in SCC-4 and SCC-25 cells. SCC-4 and SCC-25 cells were not treated as negative control (NC) or treated with 20 µM PF-4708671 for 6 h (6 h), 12 h (12 h), 18 h (18 h), 1 day (1 d), 2 days (2 d), and 3 days (3 d). Western blot analysis was performed to examine the expression levels of p-mTOR, mTOR, p-p70S6K, p70S6K, and β-actin.	28626016 30423811
Growth inhibition assay	Cell viability; PubMed: 30423811 Int J Mol Sci Inhibitory effects of various doses (0.5, 1, 2, 5, 10, 20, and 40 µM) of PF-4708671 on SCC-4 (B) and SCC-25 (C) cells were assessed using MTT assay after 72 h of treatment. Data presented are the mean and standard error of the mean of three independent experiments. * p < 0.05, p < 0.01, and * p < 0.001 indicate the statistical significance of differences between cells with and without treatment. t (red and * for SCC-4 and blue , * and *** for SCC-25).	30423811

Protocol

References

[1] Pearce LR, et al. Biochem J, 2010, 431(2), 245-255.

Solubility (25°C)

In vitro	DMSO	30 mg/mL (76.84 mM)
	Ethanol	8 mg/mL (20.49 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PF-4708671 SDF

Molecular Weight	390.41
Formula	C₁₉H₂₁F₃N₆
CAS No.	1255517-76-0
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CCC1=CN=CN=C1N2CCN(CC2)CC3=NC4=C([NH]3)C=CC(=C4)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Whether the in vivo formula "30% PEG400+0.5% Tween80+5% Propylene glycol" for S2163 is suitable for i.p. or not?
Answer:
The formula "30% PEG400+0.5% Tween80+5% Propylene glycol" on our website is an oral one. It is a suspension.

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products

LY2584702 ^New

LY2584702 is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
LY2584702 Tosylate ^New

LY2584702 Tosylate is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.
BI-D1870

BI-D1870 is an ATP-competitive inhibitor of S6 ribosome for RSK1/2/3/4 with IC50 of 31 nM/24 nM/18 nM/15 nM in cell-free assays, respectively; 10- to 100-fold selectivity for RSK than MST2, GSK-3β, MARK3, CK1 and Aurora B.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. MK-2206 2HCl induces autophagy and apoptosis in cancer cells. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
CHIR-99021 (CT99021) HCl

CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2. CHIR-99021 is a potent pharmacological activators of the Wnt/beta-catenin signaling pathway. CHIR-99021 significantly rescues light-induced autophagy and augments GR, RORα and autophagy-related proteins.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay. Everolimus induces cell apoptosis and autophagy and inhibits tumor cells proliferation.

Choose Your Country or Region

By Signaling Pathways

By product type

PF-4708671